Evista Indication:

For the prevention of osteoporosis in post-menopausal women

Evista Mechanism Of Action:

Evista binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Evista produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women. Evista also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen.

Evista Drug Interactions:

Chlorotrianisene Association not recommended
Clomifene Association not recommended
Diethylstilbestrol Association not recommended
Estradiol Association not recommended
Estriol Association not recommended
Conjugated Estrogens Association not recommended
Estropipate Association not recommended
Ethinyl Estradiol Association not recommended
Mestranol Association not recommended
Levothyroxine Evista decreases absorption of levothyroxine
Cholestyramine The resin decreases the effect of raloxifene
Colestipol The resin decreases the effect of raloxifene

Evista Food Interactions:

Avoid alcohol.

Evista Generic Name:


  • RAL
  • Raloxifene Hcl
  • Raloxifene Hydrochloride
  • Raloxifeno [Spanish]
  • Raloxifenum [Latin]
  • LY-139481

Drug Type:

Small Molecule; Approved; Investigational


Approximately 60% of an oral dose is absorbed, but presystemic glucuronide conjugation is extensive. Absolute bioavailability of raloxifene is 2.0%

Toxicity (Overdose):

Not Available

Protein Binding:



Hepatic, raloxifene undergoes extensive first-pass metabolism to the glucuronide conjugates: raloxifene-4'-glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4'-diglucuronide. No other metabolites have been detected, providing strong evidence that raloxifene is not metabolized by cytochrome P450 pathways

Half Life:


Dosage Forms of Evista:

Tablet Oral

Chemical IUPAC Name:


Organisms Affected:

Humans and other mammals

Evista to general, pharmacology

General, pharmacology..
Women's Health